TIDMPRTC
PureTech Health PLC
22 July 2021
22 July 2021
PureTech Health plc
PureTech Founded Entity Akili Releases New Gameplay Features in
the First and Only FDA-Cleared Video Game Treatment for Children
with ADHD
New EndeavorRx features released as Akili begins to scale its
commercial activities
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, today
announced that its Founded Entity, Akili Interactive ("Akili"),
introduced new gaming features and functionalities to its
EndeavorRx treatment. The new gameplay features are being released
as Akili begins its go-to market approach to bring EndeavorRx to
families and healthcare professionals at scale.
Akili leveraged its expertise in two disparate industries -
medicine and gaming - to identify opportunities to enhance the
EndeavorRx gameplay experience without changing Akili's patented
Selective Stimulus Management Engine (SSME(TM)) core technology
designed to improve attention function. The enhancements were based
on the latest trends in video game development and informed by user
insights collected across multiple forums, including playtesting,
workshops, in-depth interviews with patients and caregivers,
surveys, gameplay data and longitudinal research.
The full text of the announcement from Akili is as follows:
Akili Releases New Gameplay Features in the First and Only
FDA-Cleared Video Game Treatment for Children with ADHD
Akili delivers on commitment to unparalleled patient experiences
with continuous product enhancements
New EndeavorRx features released as Akili begins to scale its
commercial activities
BOSTON, Mass. - July 22, 2021 - Akili Interactive ("Akili" or
"Company"), maker of the first and only prescription video game
treatment, today introduced new gaming features and functionalities
to its EndeavorRx treatment following its U.S. Food and Drug
Administration (FDA) clearance in June 2020. The new gameplay
features are part of Akili's commitment to continuous product
iterations to create enjoyable, entertaining patient experiences
and are being released as Akili begins its go-to market approach to
bring EndeavorRx to families and healthcare professionals at scale.
Leveraging insights from caregivers and patients, Akili game
designers and engineers have created additional gameplay
experiences that offer exciting new quests and increased
optionality, including new personalized universes and character
choices to enhance engagement in the prescription digital
therapeutic. Enabled by the adaptive ability of digital
therapeutics and the dynamic nature of video games, these
enhancements evolve the gameplay experience for patients while
preserving the regulated core technology of the product.
Because EndeavorRx is uniquely delivered through a video game, a
number of gameplay components can be enhanced to drive user
engagement and motivation. Akili leveraged its expertise in two
disparate industries - medicine and gaming - to identify
opportunities to enhance the EndeavorRx gameplay experience without
changing Akili's patented Selective Stimulus Management Engine
(SSME(TM)) core technology designed to improve attention function.
The enhancements were based on the latest trends in video game
development and informed by user insights collected across multiple
forums, including playtesting, workshops, in-depth interviews with
patients and caregivers, surveys, gameplay data and longitudinal
research.
"Rapid product iteration is critical to creating amazing
experiences for patients and delivering on the full promise of
digital therapeutics," said Carl Gottlieb, Senior Vice President of
Engineering at Akili Interactive. "Since obtaining FDA clearance,
we've been listening and learning, and are taking a dynamic
patient-responsive approach to create an amazing experience -- from
the product to the delivery process. Because EndeavorRx is uniquely
delivered through a video game, we have nearly endless
opportunities to enhance the product and evolve it based on user
feedback and gaming trends to drive enjoyment and engagement."
New features were added to EndeavorRx, with a primary focus on
gameplay progress, increased choice and personalization. The
enhancements provide patients with more strategic challenges and
add complexity to both short-term and long-term goals to drive
motivation. Patients now have more choices during gameplay,
including selecting and unlocking new creatures and costumes,
completing new quests, and building their own universes, which
provide increased optionality and foster longer-term engagement and
interest.
"My son began playing EndeavorRx last year, and these new
features have personalized the game even further to his unique
player level and capabilities," said Kelcey Sihanourath, whose
12-year-old son has ADHD. "All of the interesting graphics and
worlds he can visit keep him motivated and the gaming experience
fresh and entertaining, despite it being an actual prescription
treatment. For example, I remember he was saving up his rewards for
one particular costume, and was so proud to show it to me once he
had earned enough points. It has been such a rewarding experience
to be able to give my son a treatment in the form of a video game
he's happy and excited about playing!"
EndeavorRx treatment was granted FDA clearance based on data
from five clinical studies in more than 600 children diagnosed with
ADHD, including a prospective, randomized, controlled study (STARS)
published in The Lancet Digital Health journal, which showed
EndeavorRx improved objective measures of attention in children
with ADHD. In March 2021, data published in Nature Digital Medicine
from a multi-site open-label study (STARS Adjunct) evaluating the
impact of EndeavorRx on symptoms and functional impairments in
children with ADHD demonstrated statistically significant
improvement in all predetermined endpoints of the study, which
included parent and clinician ratings of children's ADHD symptoms
and related impairments in daily life.
To learn more or download a guide on how to talk to a child's
doctor about EndeavorRx, please visit EndeavorRx.com .
EndeavorRx Indication and Overview
EndeavorRx is indicated to improve attention function as
measured by computer-based testing in children ages 8-12 years old
with primarily inattentive or combined-type ADHD, who have a
demonstrated attention issue. Patients who engage with EndeavorRx
demonstrate improvements in a digitally assessed measure Test of
Variables of Attention (TOVA ) of sustained and selective attention
and may not display benefits in typical behavioral symptoms, such
as hyperactivity. EndeavorRx should be considered for use as part
of a therapeutic program that may include clinician-directed
therapy, medication, and/or educational programs, which further
address symptoms of the disorder. EndeavorRx is available by
prescription only. It is not intended to be used as a stand-alone
therapeutic and is not a substitution for a child's medication.
EndeavorRx is built on the Akili Selective Stimulus Management
Engine (SSME(TM)) core technology, a proprietary technology
designed to target key attentional control systems in the brain.
SSME technology presents specific sensory stimuli and simultaneous
motor challenges designed to target and activate the neural systems
that play a key role in attention function while using adaptive
algorithms to personalize the treatment experience for each
individual patient. This enables second by second monitoring of
patient progress completing the treatment sessions, and
continuously challenges each patient to an optimized level,
encouraging patients to improve their performance. Driven by the
core belief at Akili that effective medicine can also be fun and
engaging, EndeavorRx is delivered through an action video game
experience. The captivating experience of EndeavorRx is designed to
drive engagement and compliance. To learn more about EndeavorRx,
please visit EndeavorRx.com .
About Akili
Akili is combining scientific and clinical rigor with the
ingenuity of the tech and entertainment industries to challenge the
status quo of medicine. Akili is pioneering the development of
digital treatments and care solutions to help people affected by
cognitive impairments. Akili's treatments are designed to directly
activate the networks in the brain responsible for cognitive
function and have been rigorously tested in extensive clinical
studies, including prospective randomized, controlled trials.
Driven by Akili's belief that effective medicine can also be fun
and engaging, Akili's treatments are delivered through captivating
action video game experiences. For more information, please visit
AkiliInteractive.com .
Akili, EndeavorRx, and SSME, and any logo(s) for each, are
trademarks or registered trademarks of Akili Interactive Labs, Inc.
Other trademarks are trademarks or registered trademarks of their
respective owners.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two that have received FDA clearance and
European marketing authorization, as of the date of PureTech's most
recently filed Annual Report on Form 20-F. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the
Company's unique insights into the biology of the brain, immune
and gut, or BIG, systems and the interface between those systems,
referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking
statements, including statements that relate to the Akili's goals
with respect to the EndeavorRx gameplay experience, the company's
future prospects, development plans and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks and uncertainties that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, our expectations
regarding the EndeavorRx features and gameplay enhancements, and
those risks and uncertainties described in the risk factors included
in the regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and future
business strategies of the company and the environment in which
it will operate in the future. Each forward-looking statement speaks
only as at the date of this press release. Except as required by
law and regulatory requirements, neither the company nor any other
party intends to update or revise these forward-looking statements,
whether as a result of new information, future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
# # #
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPUCAMUPGUGP
(END) Dow Jones Newswires
July 22, 2021 08:03 ET (12:03 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024